YOLFTbeta
Helixmith Co. Ltd

Helixmith Co. Ltd

084990 · KQ · Consumer Non-Cyclicals / Food & Tobacco

3,495.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close3,495.00
Open3,500.00
Day Range3,475.00 – 3,625.00
52-Week Range2,725.00 – 9,960.00
Volume91.64K
Market Cap169.22B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.80
50-Day Avg3,142.70
200-Day Avg5,509.30

About

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.

Company Details

  • SectorConsumer Non-Cyclicals
  • IndustryFood & Tobacco
  • CEOMr. Sunyoung Kim D.Phil., Ph.D.
  • Employees132
  • HeadquartersBuilding 203, Seoul, South Korea, 151-747, Korea
  • Websitehttps://www.helixmith.com

Leadership

  • Mr. Sunyoung Kim D.Phil., Ph.D.Founder, CEO & Director · b. 1955
  • Won Ho ParkPres
  • Mr. Michael NaCFO & Director of Office of Strategic Net Assessment
  • Mr. Seung-Shin Yu Ph.D.CTO , Representative Director, MD of R&D Center and Intellectual Property & Director · b. 1966
  • Jun Tae Park Ph.D.Exec. VP of Licensing & Regulatory Affairs
  • Miwon Son Ph.D.Sr. Managing Director of Phytotherapeutics
  • William O. FrankHead of Medical
  • Jong-Mook Kim Ph.D.Director of Devel. Division & Strategic Bus. Division and Director · b. 1972

Financials

Income Statement

Currency: KRW2010-12-312011-12-312012-12-312013-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.65B3.81B3.89B5.75B7.70B6.84B3.16B3.13B4.45B4.30B2.32B2.80B4.20B4.97B2.60B
Growth (%)--18.23%+2.18%+47.78%+33.93%-11.06%-53.86%-0.98%+42.45%-3.37%-46.19%+20.87%+50.08%+18.38%-47.77%
Cost of Revenue1.32B362.84M858.81M568.68M638.63M543.48M569.62M611.52M4.43B1.54B1.24B2.38B2.08B2.09B1.61B
Gross Profit3.34B2.97B3.03B5.18B7.06B6.30B2.59B2.52B23.94M2.77B1.08B416.31M2.12B2.88B988.43M
Gross Margin71.69%78.12%77.91%90.10%91.70%92.06%81.96%80.44%0.54%64.24%46.56%14.87%50.50%57.91%38.04%
Operating Expense5.82B6.21B4.71B4.80B5.89B8.18B9.46B34.03B119.98B75.94B91.26B60.92B73.07B21.01B10.88B
Operating Income-2.48B-3.24B-1.68B378.32M1.16B-1.88B-6.87B-31.52B-119.96B-73.18B-90.19B-60.50B-70.94B-18.13B-9.89B
Operating Margin-53.28%-85.13%-43.11%6.58%15.14%-27.46%-217.64%-1007.81%-2693.01%-1700.07%-3893.63%-2160.99%-1688.50%-364.46%-380.57%
EBITDA------------30.49B-53.00B-11.09B1.37B
EBITDA Margin------------1088.99%-1261.51%-223.01%52.58%
Net Income-1.69B-10.12B-4.63B265.71M256.98M-714.46M-6.50B-28.73B-107.04B-82.86B-50.94B-43.54B-64.09B-15.47B-434.92M
Net Income Margin-36.37%-265.82%-119.15%4.62%3.34%-10.44%-205.70%-918.70%-2402.89%-1924.95%-2199.16%-1555.16%-1525.33%-311.04%-16.74%
R&D591.48M443.02M428.72M438.37M--3.85B6.39B-38.18B25.30B28.10B17.15B6.64B2.56B
R&D as % of Total Revenue12.71%11.64%11.03%7.63%--121.77%204.35%-886.96%1092.16%1003.74%408.07%133.48%98.53%
Interest Expense00000000016.50B5.82B2.08B582.44M162.30M5.75M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%383.44%251.45%74.13%13.86%3.26%0.22%

Balance Sheet

Currency: KRW2010-12-312011-12-312012-12-312013-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets69.60B60.14B67.99B69.62B70.61B178.04B179.38B284.24B371.44B478.14B282.50B254.06B227.28B148.89B143.20B
Total Liabilities16.88B10.35B3.54B2.66B3.41B7.11B14.93B150.37B175.87B201.84B57.15B37.26B73.56B6.85B1.67B
Total Equity52.72B49.78B64.45B66.97B67.20B170.93B164.45B133.87B195.57B276.30B225.35B216.80B154.14B142.47B141.98B
Cash701.24M712.37M645.49M2.02B992.56M5.95B15.13B23.29B47.57B31.05B42.38B46.40B44.65B36.84B31.83B
Total Debt-----4.28B11.39B79.78B124.04B76.59B-----
Net Debt--------69.64B------

Cash Flow

Currency: KRW2010-12-312011-12-312012-12-312013-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.64B-2.19B-3.58B11.22M1.09B-2.45B-2.59B-13.46B-41.07B-48.01B-38.16B-40.74B-25.89B-16.72B-6.90B
Investing Cash Flow-8.50B2.27B-11.52B-1.09B-724.74M-149.40B6.23B-76.88B-133.94B-2.02B36.40B28.12B-17.02B40.32B-
Financing Cash Flow11.20B-81.45M15.05B2.53B-86.83M156.60B6.79B112.90B186.39B194.70B-149.29B15.16B40.92B-31.27B-
Capital Expenditure167.12M159.35M146.74M349.58M9.89B21.32B8.57B23.55B56.29B16.48B11.71B7.64B3.89B529.30M261.48M
Free Cash Flow----------68.42B-52.36B-48.38B-29.78B-17.25B-7.16B
FCF to OCF---------142.52%137.19%118.74%115.02%103.17%103.79%

Earnings

Report DateJun 3, 2009Sep 2, 2009Dec 2, 2009Mar 3, 2010Jun 2, 2010Sep 1, 2010Dec 1, 2010Mar 2, 2011Jun 1, 2011Aug 31, 2011Nov 30, 2011Feb 29, 2012May 30, 2012Aug 29, 2012Nov 28, 2012Feb 27, 2013May 29, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 28, 2014Aug 29, 2014Nov 28, 2014Feb 13, 2015May 17, 2015Aug 13, 2015Nov 13, 2015Jan 25, 2016May 13, 2016Aug 16, 2016Nov 14, 2016Feb 9, 2017May 15, 2017Aug 11, 2017Nov 14, 2017Feb 26, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Jan 23, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 13, 2020May 15, 2020Aug 14, 2020Nov 16, 2020Feb 19, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Feb 17, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Feb 16, 2023May 15, 2023Jul 13, 2023Nov 14, 2023May 16, 2024Aug 14, 2024Nov 12, 2024Feb 12, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 25, 2026May 13, 2026Aug 18, 2026
EPS Estimate---------------------------------------11.21-11.21--------446.39-465.03-473.54-443.81-167.91-304.64-352.73-403.17--403.17-----------
EPS Actual26.6056.4026.78-99.98-31.80-13.28-19.04-55.57-63.66-28.94-93.82-262.67-16.21-44.0337.30-162.48-21.1620.7340.25-30.05-33.65-6.98-24.5770.98-43.32-19.991.1571.54-28.4458.397.31-16.04-37.569.81-5.50-180.40-87.00-81.65-219.41-684.19-625.21643.09-379.45-3195.49-1067.98-668.46-549.72-657.52-40.71-619.09-114.55-582.66-335.00-256.00-294.00-277.71-263.13-269.00-199.26-875.61-92.88-82.41-42.65-33.20-16.56-22.0962.40-30.39-44.79
Surprise---------------------------------------1857.27%-6003.39%---------109.12%-33.13%75.81%-31.29%-99.51%15.97%16.65%31.12%-33.28%-----------
Timing---------------------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap169.22B
Enterprise Value84.51B
Trailing P/E0.00
Forward P/E0.00
Price / Sales59.95
Price / Book0.99
Revenue (TTM)2.89B
Gross Profit (TTM)1.06B
EBITDA-45.60B
Profit Margin0.00%
Operating Margin-1924.10%
Return on Equity-803.32%
Return on Assets-12.45%
Shares Outstanding15.96M
Shares Float31.64M
Beta0.80
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 29, 202111:10
  • Nov 13, 20201037:973
  • Apr 22, 20205:4
  • Aug 13, 20195:4
  • Jun 28, 2019485:476
  • Sep 5, 20161358:1313